Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (New York)

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque,K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, 2015, Poster B009, Session B.